Tags

Type your tag names separated by a space and hit enter

Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
Breast Cancer Res Treat 2006; 98(3):275-84BC

Abstract

BACKGROUND

Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy.

METHODS

The Danish Breast Cancer Cooperative Group (DBCG) trial 89-b randomized premenopausal patients with receptor-positive, primary breast cancer between nine cycles of CMF chemotherapy given every 3 weeks and ovarian ablation by oophorectomy. In total, 317 randomized patients were invited to take part in a longitudinal quality of life study with assessments at 1, 3, 5, 9, 15, and 24 months after randomization. The questionnaire included the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale, and additional items assessing potential symptoms not included in the standard instruments.

RESULTS

After 2 years, 260 women were alive and recurrence-free, and 196 of these (75%) had completed all six questionnaires. Overall, patients in the chemotherapy group had more symptomatology at the first three assessments (i.e., during the 6 months treatment period), except for hot flushes/sweats. There were few differences between groups at later assessments. In chemotherapy patients, the likelihood of preserving ovarian function decreased steeply with increasing age. CMF chemotherapy and ovarian ablation have similar impact on recurrence and survival.

CONCLUSION

Chemotherapy had more negative impact on health-related quality of life but preserved ovarian function in some younger patients.

Authors+Show Affiliations

The Research Unit, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark. mg02@bbh.hosp.dkNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16541325

Citation

Groenvold, Mogens, et al. "Chemotherapy Versus Ovarian Ablation as Adjuvant Therapy for Breast Cancer: Impact On Health-related Quality of Life in a Randomized Trial." Breast Cancer Research and Treatment, vol. 98, no. 3, 2006, pp. 275-84.
Groenvold M, Fayers PM, Petersen MA, et al. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat. 2006;98(3):275-84.
Groenvold, M., Fayers, P. M., Petersen, M. A., & Mouridsen, H. T. (2006). Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Research and Treatment, 98(3), pp. 275-84.
Groenvold M, et al. Chemotherapy Versus Ovarian Ablation as Adjuvant Therapy for Breast Cancer: Impact On Health-related Quality of Life in a Randomized Trial. Breast Cancer Res Treat. 2006;98(3):275-84. PubMed PMID: 16541325.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. AU - Groenvold,Mogens, AU - Fayers,Peter M, AU - Petersen,Morten Aagaard, AU - Mouridsen,Henning T, Y1 - 2006/03/16/ PY - 2005/12/28/received PY - 2006/01/02/accepted PY - 2006/3/17/pubmed PY - 2007/1/12/medline PY - 2006/3/17/entrez SP - 275 EP - 84 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 98 IS - 3 N2 - BACKGROUND: Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) chemotherapy. METHODS: The Danish Breast Cancer Cooperative Group (DBCG) trial 89-b randomized premenopausal patients with receptor-positive, primary breast cancer between nine cycles of CMF chemotherapy given every 3 weeks and ovarian ablation by oophorectomy. In total, 317 randomized patients were invited to take part in a longitudinal quality of life study with assessments at 1, 3, 5, 9, 15, and 24 months after randomization. The questionnaire included the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale, and additional items assessing potential symptoms not included in the standard instruments. RESULTS: After 2 years, 260 women were alive and recurrence-free, and 196 of these (75%) had completed all six questionnaires. Overall, patients in the chemotherapy group had more symptomatology at the first three assessments (i.e., during the 6 months treatment period), except for hot flushes/sweats. There were few differences between groups at later assessments. In chemotherapy patients, the likelihood of preserving ovarian function decreased steeply with increasing age. CMF chemotherapy and ovarian ablation have similar impact on recurrence and survival. CONCLUSION: Chemotherapy had more negative impact on health-related quality of life but preserved ovarian function in some younger patients. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/16541325/Chemotherapy_versus_ovarian_ablation_as_adjuvant_therapy_for_breast_cancer:_impact_on_health_related_quality_of_life_in_a_randomized_trial_ L2 - https://doi.org/10.1007/s10549-006-9160-9 DB - PRIME DP - Unbound Medicine ER -